ALEC - Alector, Inc.

1.14
-0.040   -3.509%

Share volume: 452,274
Last Updated: 04-25-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$1.18
-0.04
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 19%
Liquidity 52%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.72%
1 Month
-11.63%
3 Months
-32.94%
6 Months
-77.51%
1 Year
-78.33%
2 Year
-82.73%
Key data
Stock price
$1.14
P/E Ratio 
0.00
DAY RANGE
$1.13 - $1.20
EPS 
-$1.23
52 WEEK RANGE
$0.87 - $6.78
52 WEEK CHANGE
-$78.33
MARKET CAP 
185.093 M
YIELD 
N/A
SHARES OUTSTANDING 
97.321 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
2.04
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,223,218
AVERAGE 30 VOLUME 
$837,310
Company detail
CEO: Arnon Rosenthal
Region: US
Website: alector.com
Employees: 270
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the. treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases.

Recent news
loading